LOWER BACK PAIN
Dr. Rittenberg: Nonspecific treatment of nonspecific low back pain (LBP) with no patient subgrouping and no specifically designed treatments for each subgroup is analogous to giving all patients with chest pain the same treatment on the assumption that the pain is cardiac. With a nonspecific approach, some patients will get better, but some will not.
Different sources and types of back pain respond to different treatments. There is inflammatory pain, mechanical pain, neuropathic pain, and those yellow flags, the affective component of the McGill Short Form. Attention to the yellow flags is key in the acute setting because the affective component is the main link in the transition from acute to chronic pain, which is what we want to prevent.
Dr. McCarberg: How do you assess the mechanical response in patients with acute back pain?
Dr. Rittenberg: I have them bend forward and back to see which direction makes them feel better or worse. Then I prescribe exercises in the direction that makes them feel better. I also encourage them to stay active. Studies by Deyo et al and other investigators have shown that these patients do better if they avoid bed rest and stay active. [1] [2] [3] It is also important to treat their acute pain early and aggressively to prevent it from becoming chronic.
Dr. McCarberg: When patients come to my office with a complaint of back pain, I want to make a specific diagnosis, but most of the time I cannot. They have pulled something, or heard a ''pop'' in their back. They are limping. They cannot move. They are stiff. I may not know the exact cause, but I give them a nonsteroidal anti-inflammatory drug (NSAID) or a muscle relaxant and tell them to avoid doing whatever hurts for a while. If they call 3 days later and tell me they are not feeling better, I send them to physical therapy. How do I know if it is a strained ligament, an injured sacroiliac joint, or an inflamed facet joint? And how will that change the way I handle the follow-up phone call from the patient who is not feeling better?
Dr. Rittenberg: It is probably not that important to know the exact tissue diagnosis at the first visit, but knowing the mechanical presentation is. Constant pain suggests an inflammatory component. If there is a lot of inflammation in the disc, I will be more aggressive and prescribe either an oral steroid or an NSAID. If the pain is associated with specific activities, such as prolonged sitting or bending over, I will tell the patient from day 1 to do exercises in the opposite direction to off-load the symptom or to use a lumbar roll to take pressure off the disc.
Dr. Kuritzky: It is always wise to strive for the best diagnostic specificity and to target therapy as closely as possible to the diagnosis. However, I am not convinced that specific diagnostic classification improves outcome. I am also not sure about the use of oral steroids. The review data have not shown improvements in outcome in acute back pain.
Dr. Rittenberg: I agree that there is no hard evidence for improved outcomes with oral steroids, but they are widely used.
Dr. McCarberg: They are used all the time in primary care. In our algorithm, which we believe is evidence based, there is some evidence that oral steroids work for acute LBP that goes below the knee. Oral steroids are also used for buttock pain and acute nonspecific LBP even if the evidence is not very strong.
As for affect, we can identify it as a yellow flag very early. We see it in a patient with whiplash who says he needs to be away from work for 8 weeks, and we can pretty much tell that he is not going to be any better 8 weeks from now. Is there anything we can do early on that would make a difference?
Dr. Rittenberg: I think we all know who those patients are when they come in. They do not necessarily have to check off the right box on the McGill form. Their anxiety is obvious, and reassuring them is a huge part of treatment. I try to get them involved in physical therapy much earlier than I would a patient without anxiety, and I make sure the therapists understand that.
Dr. McCarberg: We do not have that relationship with physical therapy. We write a referral that says, ''Evaluate and treat,'' but we have no idea what is going on. We do not know which physical therapist or facility the patient is going to.
Dr. Kuritzky: There are studies showing that people who are unhappy at work, with life, or with a spouse are more likely to have persistent symptoms. 4, 5 On the other hand, we should not deny appropriate intervention to people who are unhappy. There are no data showing that a different type of intervention for an unhappy person is going to improve the outcome.
Dr. Rittenberg: Actually, you treat them more aggressively. You treat their pain, and you pay attention to the affective component. Studies have shown that there is a link between the affective component and moving from acute to chronic pain. 6 Dr. Kulich: Outcome is not necessarily what you can do, but what you should not do with these patients. We should avoid reinforcing palliative or passive activities that fail to provide improved outcomes. Unfortunately, many of these patients receive multiple trigger point injections with absolutely no evidence base at all.
Dr. Viscusi: It is important to engage patients in a conversation about acute versus chronic pain, how we try to prevent acute pain from becoming chronic, and how we use whatever we have at our disposal to accomplish that. But it is critical for the patient to feel like a participant and be engaged in those decisions.
I agree it is a difficult decision to implement therapies for which we do not have much evidence, such as trigger points. However, there are often situations in pain management where we know there is a clinical benefit to the patient despite little solid evidence.
Dr. Barkin: Because we are also talking about improving the standard of care, I want to emphasize that primary care physicians should be able to order clinical urine drug testing using liquid chromatography and mass spectrometry to find out if patients are using the drug they claim to be taking or if they are using the drug that the physician prescribed. Every primary care physician has encountered a patient who knows how to fill out the McGill Pain Questionnaire and what to say to get a prescription for the drug he wants. ''Oh, I can't take an NSAID because I have difficulty breathing. I have blood in my urine. I had 5 NSAIDs on board and none of them did anything. The only drug I want, doctor, is this extended-release opioid, this immediate-release opioid, this muscle relaxant, and don't forget the diazepam, trade name only.'' This is reality, and we see it every day. Clinicians need to know that tools are available to improve the standard of care, and they have to be able to handle the patient with an agenda. They can handle the effect by asking patients if their pain makes them feel depressed, agitated, irritable, assaulted, or angry or if it interferes with their social life. That is different from the person who has genuine, aberrant, compulsive, impaired drug use or is seeking control.
UNMET NEEDS IN PAIN MANAGEMENT
Dr. McCarberg: When the cyclooxygenase (COX)-2selective agents came on the market, there was a huge increase in prescriptions for nonselective NSAIDs and COX-2 inhibitors. However, when the rofecoxib data came out, there was a huge loss in new prescriptions and refills for acute pain drugs. Are we undertreating pain as a result? Is there something we can do that would better meet the need for pain relief?
Dr. Weaver: There is a tremendous unmet need, and it probably explains the significant and somewhat unexpected use of topical NSAIDs just in the short time they have been on the market in the United States. Gastrointestinal (GI) safety drove the COX-2 market, but the cardiovascular concerns, first with rofecoxib and now with all NSAIDs, have led to a significant decline in the use of all these oral agents. We have to focus as much on the art of medicine as on the science of medicine. We should listen to our patients, show compassion, and reassure patients before we order more tests and more medications.
Dr. Nicholson: I think there is an unmet need on both sides. More often than not, patients have unrealistic expectations. When I see patients for the first time, I always ask them what their expectations are. Some patients, even if they have had pain for 10 years, will say, ''I want you to eliminate all my pain.'' The art of medicine is sitting down and talking to them in a realistic fashion. This also applies to patients with acute pain. You have to recognize that some patients may develop chronic symptoms but that the goal of therapy is to manage their symptoms so that they can remain functional.
Dr. McCarberg: Do you think that the emerging therapies and the topical formulations are going to be helpful, given the risks and the fact that there is an unmet need?
Dr. Weaver: I think they will be helpful. The question is safety. We always have to look at the risk/benefit ratio of any drug we prescribe.
Dr. McCarberg: How do I, as a primary care doctor, decide whether or when to use a new drug that looks promising? Should I try to get preauthorization or should I wait a year? If it is a good drug, waiting a year is not good for my patients. If it is a hazardous drug, it is prudent to wait a year.
Dr. Weaver: You look at the clinical trials and, if possible, speak with the investigators. They are usually able to tell you if there is a safety issue. However, unusual and sometimes serious side effects emerge over time. You may not see them with 600 patients in a clinical trial, but you may see a few in a 10,000-patient trial. That is exactly what happened with the cardiovascular outcomes in the Vioxx Gastrointestinal Outcomes Research trial evaluating rofecoxib. 7 Dr. Viscusi: Very often, the trial safety profile is based on the relatively short-term administration of a drug, and that is a major issue. It was prolonged use of the coxibs that changed their risk profile dramatically. Because you will not get that information for years, you would inevitably be denying patients a useful drug if you wait for long-term safety data. There are still many patients who beg for rofecoxib because the side effect profile was acceptable to them. The distinction between short-and long-term use is really important.
Moreover, I have not seen many patients who took rofecoxib going to opioids because the side effect profile of opioids was far less tolerable than what they experienced with rofecoxib.
Dr. McCarberg: I agree. Many of my patients just dropped out. They opted for more pain rather than pain control with a higher risk drug. They accepted lower quality of life because they thought the risk was so much higher.
Dr. Kuritzky: The issue is recognizing the balance of risk and benefit and discussing that with your patient.
Dr. McCarberg: How do you have that conversation in primary care? How do you explain risks and benefits so that patients understand what they are and use the information to make an important decision for themselves?
Dr. Weaver: The GI risk is significantly higher than the cardiac event risk. It is generally accepted that a GI bleed has a mortality rate between 5% and 10%, which is a significant risk in itself, even though cardiac risks garner more attention.
We should remember that all the data we have on NSAIDs were obtained from very small short-term trials. It was not until the large trials evaluating the coxibs that we began to see cardiac events, which have since been seen with virtually all the NSAIDs. 8 We need longer duration trials, with comparative agents with and without aspirin, and at high doses because that is where the problems seem to have occurred. We also have to look at quality of life issues when we discuss the risk/benefit ratio with our patients.
Dr. McCarberg: We also have to understand that risk in a clinical trial, in which patients are required to take the study drug every day, is not the same as risk in the real world, where patients do not take their medications every day. They take them based on symptoms; therefore, they may go days or weeks without taking medication. That probably carries a lower cardiovascular risk, but we do not have data on that. I worry about undermanaging pain because many patients believe that their risk for a heart attack or stroke is so huge.
Dr. Weaver: All you need to do is look at the huge amount of money patients spend on alternative agents, none of which have been proven to be of benefit or evaluated by the US Food and Drug Administration to any great degree. Billions of dollars are spent each year on unproven remedies for arthritis.
ACUTE VERSUS CHRONIC
Dr. McCarberg: What exactly is the difference between acute and chronic? We can certainly tell it when we see it in primary care, but we do not know exactly. There are all sorts of definitions that come under time frame-3 and 6 months-but I do not know if that is very useful because we certainly sense it much earlier than that. Also, when does acute become chronic?
Dr. Viscusi: If it lasts beyond 30 days, I have trouble considering it an acute situation. If it lasts less than 30 days, it is definitely within the acute time frame.
Dr. Nicholson: I agree. Once you are looking at 30 days, the whole idea of waiting 3 months to determine if the pain is chronic does nothing but set the patient up for a poor outcome. The behavior patterns are set well before then.
Dr. McCarberg: This is analogous to postherpetic neuralgia, which is not defined as such until 3 months after the onset of the rash. Yet patients are clearly postherpetic much earlier than that.
Dr. Kuritzky: There is also a hyperacute phase that is essentially neglected in the literature. I see patients who have what I call hyperacute back pain. They just stepped down the stairs wrong or they bent over and cannot straighten up. Usually, the pain lasts no more than 48 hours. Reluctant as I am to use opioids in the management of chronic nonmalignant pain, I think there is an appropriate role for intensive analgesia, muscle relaxation, or a combination of both in the hyperacute phase.
